Outcome Following Truncation of Asparaginase
NCT03987542 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1401
Last updated 2022-05-20
Summary
This study aimed to investigate the outcome of patients who had their asparaginase treatment truncated in the NOPHO ALL2008 protocol.
Conditions
- Relapse Leukemia
Sponsors & Collaborators
-
Birgitte Klug Albertsen
lead OTHER
Eligibility
- Min Age
- 1 Year
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-07-31
- Primary Completion
- 2020-06-30
- Completion
- 2020-06-30
Countries
- Denmark
Study Locations
More Related Trials
-
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
NCT00136435 ·Status: COMPLETED ·Phase: PHASE2
-
A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia
NCT01272440 ·Status: UNKNOWN
-
Multicenter Clinical Trial for Adult Ph-negative ALL. Non-intensive But Non-iterruptive Treatment
NCT01193933 ·Status: UNKNOWN ·Phase: NA
-
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
NCT00982514 ·Status: UNKNOWN
-
Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol
NCT04825548 ·Status: COMPLETED
-
Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase -An ALLTogether Pilot Study
NCT04843150 ·Status: COMPLETED
-
ALL Adult Consortium Trial: Adult ALL Trial
NCT00476190 ·Status: COMPLETED ·Phase: PHASE2
-
MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate
NCT02067143 ·Status: COMPLETED ·Phase: PHASE2
-
Intensified Post Remission Therapy Containing PEG-Asparaginase
NCT00184041 ·Status: COMPLETED ·Phase: PHASE2
-
Real World Asparaginase Therapy Toxicity
NCT07008027 ·Status: NOT_YET_RECRUITING
-
A Study of Children With Refractory or Relapsed ALL
NCT00187083 ·Status: COMPLETED ·Phase: PHASE3
-
Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL
NCT01225874 ·Status: COMPLETED ·Phase: NA
-
Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)
NCT03668392 ·Status: TERMINATED ·Phase: PHASE2
-
NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
NCT00548431 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
NCT04079296 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS
NCT01540812 ·Status: COMPLETED
-
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
NCT04358393 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
NCT00549848 ·Status: COMPLETED ·Phase: PHASE3
-
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
NCT01743859 ·Status: COMPLETED ·Phase: PHASE2
-
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
NCT00439296 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)
NCT04417517 ·Status: TERMINATED ·Phase: PHASE1
-
Treatment of Adult ALL With an MRD-directed Programme.
NCT00358072 ·Status: COMPLETED ·Phase: PHASE2
-
Outcomes in Bone Marrow Aplasia.
NCT06493981 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Treatment of Acute Leukemia Relapse After Allotransplantation
NCT01369368 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
NCT00002499 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3